Alvotech (NASDAQ: ALVO) Stock Competitors & Peer Comparison

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while TAK trades at $17.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas TAK's P/E ratio is 12.52. In terms of profitability, ALVO's ROE is +0.35%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ALVO is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check TAK's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while HLN trades at $9.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas HLN's P/E ratio is 18.28. In terms of profitability, ALVO's ROE is +0.35%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ALVO is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check HLN's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while TEVA trades at $37.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas TEVA's P/E ratio is 12.54. In terms of profitability, ALVO's ROE is +0.35%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ALVO is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check TEVA's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while VTRS trades at $16.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas VTRS's P/E ratio is 6.39. In terms of profitability, ALVO's ROE is +0.35%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ALVO is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check VTRS's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ALVO's ROE is +0.35%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ALVO is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check ITCI's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ALVO's ROE is +0.35%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ALVO is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check CTLT's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ELAN trades at $22.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ELAN's P/E ratio is 20.91. In terms of profitability, ALVO's ROE is +0.35%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ALVO is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check ELAN's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while RDY trades at $12.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas RDY's P/E ratio is 20.30. In terms of profitability, ALVO's ROE is +0.35%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ALVO is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check RDY's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while LNTH trades at $100.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas LNTH's P/E ratio is 16.93. In terms of profitability, ALVO's ROE is +0.35%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ALVO is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check LNTH's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while AMRX trades at $17.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas AMRX's P/E ratio is 19.62. In terms of profitability, ALVO's ROE is +0.35%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ALVO is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check AMRX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while INDV trades at $38.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas INDV's P/E ratio is 10.61. In terms of profitability, ALVO's ROE is +0.35%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ALVO is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check INDV's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while SUPN trades at $47.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas SUPN's P/E ratio is 15.64. In terms of profitability, ALVO's ROE is +0.35%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ALVO is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check SUPN's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while RGC trades at $5.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas RGC's P/E ratio is -356.34. In terms of profitability, ALVO's ROE is +0.35%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ALVO is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check RGC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while BHC trades at $6.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas BHC's P/E ratio is 1.58. In terms of profitability, ALVO's ROE is +0.35%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ALVO is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check BHC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ALVO's ROE is +0.35%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ALVO is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check DCPH's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while HCM trades at $12.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas HCM's P/E ratio is 4.59. In terms of profitability, ALVO's ROE is +0.35%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ALVO is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check HCM's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ALVO's ROE is +0.35%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ALVO is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check AVDL's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ALVO's ROE is +0.35%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ALVO is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check EMBCV's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ALVO's ROE is +0.35%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ALVO is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check DVAX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while PRGO trades at $12.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas PRGO's P/E ratio is 5.07. In terms of profitability, ALVO's ROE is +0.35%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ALVO is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check PRGO's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ANIP trades at $75.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ANIP's P/E ratio is 9.14. In terms of profitability, ALVO's ROE is +0.35%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ALVO is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check ANIP's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas TARO's P/E ratio is 30.05. In terms of profitability, ALVO's ROE is +0.35%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ALVO is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check TARO's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while HROW trades at $39.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas HROW's P/E ratio is 437.33. In terms of profitability, ALVO's ROE is +0.35%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ALVO is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check HROW's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while PAHC trades at $34.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas PAHC's P/E ratio is 11.54. In terms of profitability, ALVO's ROE is +0.35%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ALVO is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check PAHC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while CRON trades at $3.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas CRON's P/E ratio is 30.10. In terms of profitability, ALVO's ROE is +0.35%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ALVO is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check CRON's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ETON trades at $42.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ETON's P/E ratio is -594.00. In terms of profitability, ALVO's ROE is +0.35%, compared to ETON's ROE of -0.06%. Regarding short-term risk, ALVO is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check ETON's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while PCRX trades at $23.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas PCRX's P/E ratio is 9.12. In terms of profitability, ALVO's ROE is +0.35%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ALVO is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check PCRX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ALVO's ROE is +0.35%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ALVO is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check PETQ's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while AMPH trades at $20.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas AMPH's P/E ratio is 6.82. In terms of profitability, ALVO's ROE is +0.35%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ALVO is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check AMPH's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while COLL trades at $28.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas COLL's P/E ratio is 3.26. In terms of profitability, ALVO's ROE is +0.35%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ALVO is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check COLL's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, EVO has a market cap of 778M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while EVO trades at $2.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas EVO's P/E ratio is -3.09. In terms of profitability, ALVO's ROE is +0.35%, compared to EVO's ROE of -0.24%. Regarding short-term risk, ALVO is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check EVO's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while IRWD trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas IRWD's P/E ratio is 5.54. In terms of profitability, ALVO's ROE is +0.35%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ALVO is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check IRWD's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ALVO's ROE is +0.35%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ALVO is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check BDSI's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while EOLS trades at $8.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas EOLS's P/E ratio is -25.71. In terms of profitability, ALVO's ROE is +0.35%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ALVO is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check EOLS's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while AQST trades at $4.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas AQST's P/E ratio is -6.93. In terms of profitability, ALVO's ROE is +0.35%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ALVO is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check AQST's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while TLRY trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas TLRY's P/E ratio is -4.32. In terms of profitability, ALVO's ROE is +0.35%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ALVO is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check TLRY's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while CGC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas CGC's P/E ratio is -0.62. In terms of profitability, ALVO's ROE is +0.35%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ALVO is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check CGC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while KMDA trades at $7.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas KMDA's P/E ratio is 19.66. In terms of profitability, ALVO's ROE is +0.35%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ALVO is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check KMDA's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while TKNO trades at $7.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas TKNO's P/E ratio is -23.84. In terms of profitability, ALVO's ROE is +0.35%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ALVO is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check TKNO's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ALVO's ROE is +0.35%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ALVO is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check ALIM's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while EMBC trades at $5.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas EMBC's P/E ratio is 1.83. In terms of profitability, ALVO's ROE is +0.35%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ALVO is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check EMBC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ALVO's ROE is +0.35%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ALVO is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check LNDC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ACB trades at $3.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ACB's P/E ratio is -7.80. In terms of profitability, ALVO's ROE is +0.35%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ALVO is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check ACB's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ORGO trades at $1.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ORGO's P/E ratio is 60.33. In terms of profitability, ALVO's ROE is +0.35%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ALVO is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check ORGO's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ALVO's ROE is +0.35%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ALVO is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check TYHT's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while SIGA trades at $2.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas SIGA's P/E ratio is 10.63. In terms of profitability, ALVO's ROE is +0.35%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ALVO is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check SIGA's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while OGI trades at $1.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas OGI's P/E ratio is -4.96. In terms of profitability, ALVO's ROE is +0.35%, compared to OGI's ROE of -0.07%. Regarding short-term risk, ALVO is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check OGI's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while LFCR trades at $4.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas LFCR's P/E ratio is -4.46. In terms of profitability, ALVO's ROE is +0.35%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ALVO is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check LFCR's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas REPH's P/E ratio is -8.04. In terms of profitability, ALVO's ROE is +0.35%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ALVO is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check REPH's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while DERM trades at $6.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas DERM's P/E ratio is -17.38. In terms of profitability, ALVO's ROE is +0.35%, compared to DERM's ROE of -0.36%. Regarding short-term risk, ALVO is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check DERM's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while CRDL trades at $1.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas CRDL's P/E ratio is -5.41. In terms of profitability, ALVO's ROE is +0.35%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, ALVO is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check CRDL's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas THTX's P/E ratio is -28.83. In terms of profitability, ALVO's ROE is +0.35%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ALVO is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check THTX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ALVO's ROE is +0.35%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ALVO is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check ASRT's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while CPIX trades at $7.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas CPIX's P/E ratio is -19.90. In terms of profitability, ALVO's ROE is +0.35%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ALVO is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check CPIX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ALVO's ROE is +0.35%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ALVO is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check SCTL's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while BGM trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas BGM's P/E ratio is -1.01. In terms of profitability, ALVO's ROE is +0.35%, compared to BGM's ROE of -0.07%. Regarding short-term risk, ALVO is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check BGM's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas PROC's P/E ratio is 1.53. In terms of profitability, ALVO's ROE is +0.35%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ALVO is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check PROC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ALVO's ROE is +0.35%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ALVO is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check OPTN's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ALVO's ROE is +0.35%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ALVO is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check ZOM's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ALVO's ROE is +0.35%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ALVO is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check GRVI's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ZYBT trades at $1.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, ALVO's ROE is +0.35%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ALVO is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check ZYBT's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while TLPH trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas TLPH's P/E ratio is -4.52. In terms of profitability, ALVO's ROE is +0.35%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, ALVO is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check TLPH's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ALVO's ROE is +0.35%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ALVO is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check ZYNE's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ALVO's ROE is +0.35%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ALVO is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check SSIC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ALVO's ROE is +0.35%, compared to VLNS's ROE of N/A. Regarding short-term risk, ALVO is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check VLNS's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ALVO's ROE is +0.35%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ALVO is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check DRRX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while INCR trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas INCR's P/E ratio is -2.23. In terms of profitability, ALVO's ROE is +0.35%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ALVO is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check INCR's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ALVO's ROE is +0.35%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, ALVO is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check JUPW's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while CPHI trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas CPHI's P/E ratio is -1.72. In terms of profitability, ALVO's ROE is +0.35%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, ALVO is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check CPHI's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas QLI's P/E ratio is -4.92. In terms of profitability, ALVO's ROE is +0.35%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ALVO is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check QLI's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ALVO's ROE is +0.35%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ALVO is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check HEXO's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while RMTI trades at $7.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas RMTI's P/E ratio is -7.42. In terms of profitability, ALVO's ROE is +0.35%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, ALVO is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check RMTI's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while AYTU trades at $2.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas AYTU's P/E ratio is -1.23. In terms of profitability, ALVO's ROE is +0.35%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ALVO is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check AYTU's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while TXMD trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas TXMD's P/E ratio is 105.96. In terms of profitability, ALVO's ROE is +0.35%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ALVO is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check TXMD's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ALVO's ROE is +0.35%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ALVO is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check CYTH's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ALVO's ROE is +0.35%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ALVO is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check EVOK's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while OPTH trades at $4.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas OPTH's P/E ratio is -17.38. In terms of profitability, ALVO's ROE is +0.35%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, ALVO is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check OPTH's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ALVO's ROE is +0.35%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, ALVO is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check ACRX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, ALVO's ROE is +0.35%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, ALVO is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check BFRIW's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while COSM trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas COSM's P/E ratio is -0.29. In terms of profitability, ALVO's ROE is +0.35%, compared to COSM's ROE of -0.96%. Regarding short-term risk, ALVO is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check COSM's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ALVO's ROE is +0.35%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ALVO is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check AGRX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ALVO's ROE is +0.35%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ALVO is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check NLTX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas LCI's P/E ratio is -0.04. In terms of profitability, ALVO's ROE is +0.35%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ALVO is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check LCI's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ALVO's ROE is +0.35%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ALVO is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check ADMP's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while YCBD trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas YCBD's P/E ratio is -1.49. In terms of profitability, ALVO's ROE is +0.35%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ALVO is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check YCBD's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while GELS trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas GELS's P/E ratio is -1.14. In terms of profitability, ALVO's ROE is +0.35%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ALVO is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check GELS's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas MNK's P/E ratio is -0.44. In terms of profitability, ALVO's ROE is +0.35%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ALVO is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check MNK's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ALVO's ROE is +0.35%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ALVO is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check FLGC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while UPC trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas UPC's P/E ratio is -0.75. In terms of profitability, ALVO's ROE is +0.35%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ALVO is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check UPC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while SBFM trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas SBFM's P/E ratio is -0.20. In terms of profitability, ALVO's ROE is +0.35%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, ALVO is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check SBFM's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ALVO's ROE is +0.35%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ALVO is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check PLXP's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while SHPH trades at $4.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas SHPH's P/E ratio is -0.20. In terms of profitability, ALVO's ROE is +0.35%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ALVO is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check SHPH's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ALVO's ROE is +0.35%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ALVO is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check ATNX's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while SNOA trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas SNOA's P/E ratio is -1.16. In terms of profitability, ALVO's ROE is +0.35%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ALVO is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check SNOA's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while PROCW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas PROCW's P/E ratio is N/A. In terms of profitability, ALVO's ROE is +0.35%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ALVO is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check PROCW's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while RDHL trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas RDHL's P/E ratio is 0.12. In terms of profitability, ALVO's ROE is +0.35%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ALVO is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check RDHL's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while SXTC trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas SXTC's P/E ratio is 1.18. In terms of profitability, ALVO's ROE is +0.35%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, ALVO is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check SXTC's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while YCBD-PA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, ALVO's ROE is +0.35%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, ALVO is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for ALVO.Check YCBD-PA's competition here

Alvotech (NASDAQ: ALVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVO stands at 1.4B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, ALVO is priced at $3.95 on the NASDAQ, while CYTHW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVO currently has a P/E ratio of -11.79, whereas CYTHW's P/E ratio is N/A. In terms of profitability, ALVO's ROE is +0.35%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, ALVO is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for ALVO.Check CYTHW's competition here